01. Industrializing Off-the-Shelf Cell Line-based Therapies

02. Cell Engineering Platforms: viral & non-viral
Diverse genetic engineering technologies to harness the power of cell lines

03. A novel NK cell line platform, NK101
†NK101 is a clonal cell line derived from a patient with extranodal NK/T cell lymphoma

● Features of CD56dimCD62L+ polyfunctional NK subset at the middle stage of maturation
● Distinct immunostimulatory and proliferative potentials
04. NK cell platforms in the field: competitive analysis
NK cell lines provide genuine “off-the-shelf” therapeutics w/ “industrial scalability”

05. NK cell lines in the field: competitive analysis
NK101 demonstrates the best-in-class scalability & immunostimulatory potential
NK101 provides the most robust platform for multifunctional genetic engineering

06. 1st generation engineering approach for NK101

07. 2nd generation engineering approach for NK101

08. 2nd generation engineering approach for NK101
Universal & off-the-shelf NK cell therapeutics optimized for mAb combination

● HLA, human leukocyte antigen; KO, knockout; CAR, chimeric antigen receptor; mAb, monoclonal antibody; TRAIL, TNF-related apoptosis inducing ligand; CD, cytosine deaminase; 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; ha, high-affinity
09. NK104: HLA-edited, CD16V-CAR modified NK101
